Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years
Overview
Authors
Affiliations
Importance: Rotavirus infection is the global leading cause of diarrhea-associated morbidity and mortality among children younger than 5 years.
Objectives: To examine the extent of rotavirus infection among children younger than 5 years by country and the number of deaths averted because of the rotavirus vaccine.
Design, Setting, And Participants: This report builds on findings from the Global Burden of Disease Study 2016, a cross-sectional study that measured diarrheal diseases and their etiologic agents. Models were used to estimate burden in data-sparse locations.
Exposure: Diarrhea due to rotavirus infection.
Main Outcomes And Measures: Rotavirus-associated mortality and morbidity by country and year and averted deaths attributable to the rotavirus vaccine by country.
Results: Rotavirus infection was responsible for an estimated 128 500 deaths (95% uncertainty interval [UI], 104 500-155 600) among children younger than 5 years throughout the world in 2016, with 104 733 deaths occurring in sub-Saharan Africa (95% UI, 83 406-128 842). Rotavirus infection was responsible for more than 258 million episodes of diarrhea among children younger than 5 years in 2016 (95% UI, 193 million to 341 million), an incidence of 0.42 cases per child-year (95% UI, 0.30-0.53). Vaccine use is estimated to have averted more than 28 000 deaths (95% UI, 14 600-46 700) among children younger than 5 years, and expanded use of the rotavirus vaccine, particularly in sub-Saharan Africa, could have prevented approximately 20% of all deaths attributable to diarrhea among children younger than 5 years.
Conclusions And Relevance: Rotavirus-associated mortality has decreased markedly over time in part because of the introduction of the rotavirus vaccine. This study suggests that prioritizing vaccine introduction and interventions to reduce diarrhea-associated morbidity and mortality is necessary in the continued global reduction of rotavirus infection.
Evaluation of Liposome-Encapsulated Vancomycin Against Methicillin-Resistant .
Erdene E, Munkhjargal O, Batnasan G, Dorjbal E, Oidov B, Byambaa A Biomedicines. 2025; 13(2).
PMID: 40002791 PMC: 11853440. DOI: 10.3390/biomedicines13020378.
Hubbard S, Wolf J, Oza H, Arnold B, Freeman M, Levy K Environ Health Perspect. 2025; 133(2):26001.
PMID: 39903556 PMC: 11793162. DOI: 10.1289/EHP14502.
Anza D, Esposito M, Bertolazzi G, Fallucca A, Genovese C, Maniscalco G Vaccines (Basel). 2025; 13(1).
PMID: 39852842 PMC: 11769460. DOI: 10.3390/vaccines13010063.
Vita D, Lemos M, Neto Z, Evans M, Francisco N, Fortes F Viruses. 2025; 16(12.
PMID: 39772256 PMC: 11680217. DOI: 10.3390/v16121949.
Molecular Characterization and Pathogenicity Analysis of Porcine Rotavirus A.
Lv Y, Tong Z, Liu J, Zhang Z, Wang C, Zeng Y Viruses. 2025; 16(12.
PMID: 39772152 PMC: 11680200. DOI: 10.3390/v16121842.